Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review

Alfredo Pennica1 · Giulia Conforti2 · Francesca Falangone2 · Antonio Martocchia2 · Laura Tafaro2 · Alberto Sentimentale2 · Valentina Marini2 · Aldo Pezzuto2 · Valerio Spuntarelli2 · Paolo Martelletti2

Accepted: 20 May 2020/Published online: 29 May 2020
© Springer Nature Switzerland AG 2020

Abstract
Coronavirus disease 2019 (COVID-19) is a viral infection which is rapidly spreading on a global scale and causing a severe acute respiratory syndrome that affects today about four and a half million registered cases of people around the world. The aim of this narrative review is to provide an urgent guidance for the doctors who take care of these patients. Recommendations contained in this protocol are based on limited, non-definitive, evidence and experience-based opinions about patients with low and medium intensity of care. A short guidance on the management of COVID-19 is provided for an extensive use in different hospital settings. The evidence-based knowledge of COVID-19 is rapidly evolving, and we hope that, in the near future, a definitive and most efficacious treatment will be available including a specific vaccine for SARS-CoV-2.

Keywords COVID-19 · Low-medium intensity of care · Therapy · Management

Introduction
Coronavirus disease 2019 (CoViD-19) is a rapidly spreading viral infection causing a severe acute respiratory syndrome that affects today about four and half million people globally [1]. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, we aim to provide in this narrative review an evidence and experience-based guidance for clinicians involved in the care of COVID-19-positive adults in a setting of low/medium intensity of care.

Classification and Risk Stratification for Management of COVID-19

As the WHO stated, a confirmed COVID-19 case is defined as “a case with laboratory confirmation for SARS-CoV-2 infection carried out at the reference laboratory, regardless of the clinical signs and symptoms presented” [2].

The clinical presentation is heterogeneous: about 80% of confirmed cases are considered “mild”, involving mostly cold-like symptoms to mild pneumonia; 15% are “severe”, involving serious pneumonia and shortness of breath; the remaining 5% develop respiratory failure, septic shock, and/or multi-organ failure—“critical cases”—potentially resulting in death [3]. The second week appears to be the most dangerous for a potential clinical worsening, according to the data [4]. Cases of asymptomatic infection are also possible, but their frequency is not known at present [5].

In accord to the WHO definitions [2], we may have the following:

- Uncomplicated disease: limited to upper respiratory tract viral infection; nontypical symptoms such as fever, malaise, cough, pharyngodynia, nasal congestion, headache, or muscle pain. On rare occasion, patients may also...
present with diarrhea, nausea, and vomiting. No signs of severe pneumonia. Adolescent or adult immunosuppressed may exhibit atypical symptoms.

- Mild pneumonia: clinical and/or radiological diagnosis of pneumonia but no signs of severe pneumonia and no need for supplemental oxygen (SpO2 > 90% in air). The diagnosis is clinical, and chest imaging is helpful to rule out complications.
- Severe pneumonia that includes fever or suspected respiratory infection, plus any of the following conditions:
  - Respiratory rate > 30 acts/min
  - Dyspnea
  - SpO2 < 90% in air
- ARDS (acute respiratory distress syndrome) (definition of Berlin 2012) [6]:
  - New onset or worsening respiratory symptoms, within a week of exposure to the causative agent
  - Imaging (radiography, CT, pulmonary ultrasound): bilateral opacities not related to cardiogenic edema, effusions, atelectasis, and pulmonary nodules
  - Cause of edema not referable to heart failure or fluid overload. Accurate instrumental evaluation (e.g., echocardiography) is necessary to exclude cardiogenic pulmonary edema in the absence of risk factors [6]
  - Oxygenation (adults):
    - Mild ARDS, 201 mmHg < P/F ≤ 300 mmHg
    - Moderate ARDS, 101 mmHg < P/F ≤ 200 mmHg
    - Severe ARDS, P/F ≤ 100 mmHg

To evaluate the severity of COVID and to determine the correct management, we may refer to slightly different scales [7, 8], and we refer to the Modified Early Warning Score (MEWS), an exclusively clinical evaluation system [8].

The MEWS is a rapid and simple application tool, which provides a useful aid in deciding on the correct allocation of the patient, based on the intensity of monitoring and treatment required (see Table 1). Using MEWS score, we may have the following: stable patient (score 0–2), instable patient (score 3–4), and critical conditions (score ≥ 5).

Another tool being used in Italy, though not externally validated, is the Brescia-COVID Respiratory Severity Scale (BCRS) (Table 2) [9]. This is a stepwise approach to managing patients with confirmed/presumed COVID-19 pneumonia. On the basis of four clinical-instrumental criteria, the patient is assigned to one of eight levels of care.

Levels 0–3 are managed in a non-critical area, while levels from 4 to 8, inclusive, require intensive care (https://cdn-web-img.mdcalc.com/content/BRSS).

In our low-medium intensity care unit, we manage cases of mild/severe COVID-19 pneumonia (MEWS 0–3; BCRS 1–3) that require medical support therapy, oxygen therapy, frequent monitoring of vital parameters and oxygenation with pulse oximetry, and arterial gas analysis. Continuous clinical reassessment is essential because of the high risk of sudden deterioration.

### Therapeutic Approach

At present, there are no antiviral drugs registered for use in patients with COVID-19. Supportive care [10–12] is standard of care, and the currently available drugs are as follows:

- Protease inhibitors (lopinavir/ritonavir; darunavir + ritonavir; darunavir/cobicistat) [10], already used for the chronic treatment of HIV infection and promising treatment option for COVID-19 infections, based on the proven efficacy against SARS-CoV (in combination with ribavirin) [13]. Clinical evidence however remains limited. The effectiveness of lopinavir/ritonavir is suggested by anecdotal cases [14]. In a similar way, anecdotal cases suggest how this administration is able to reduce the viral load of COVID-19 very quickly [15]. Three randomized, open-label clinical trials are currently listed on https://clinicaltrials.gov/ evaluating darunavir/cobicistat as a potential therapeutic option for COVID-19.
- Chloroquine or hydroxychloroquine, drugs used in malaria, amebiasis, and in some diseases with autoimmune pathogenesis; clinical studies have shown the activity in vitro and in the animal model of chloroquine phosphate as an antiviral against the SARS virus [16, 17] and avian influenza [18]. Despite the lack of clear evidence of benefit, hydroxychloroquine is recommended off label for the treatment of COVID-19 by the Chinese National guidelines [19, 20], and the US Food and Drug Administration has issued an Emergency Use Authorization for the treatment of adult patient with COVID-19. By contrast, the IDSA (Infectious Disease Society of America) recently concluded that because of insufficient data, they could not recommend any particular treatment for patients with COVID-19 [21].
- Azithromycin, an antibiotic belonging to the macrolide family [22].
- Tocilizumab, monoclonal antibody, already used in the treatment of severe syndromes caused by release of cytokines induced by CAR-T lymphocytes (chimeric antigen receptor T cell) [23].
- Remdesivir (GS-5734) is a broad-spectrum antiviral nucleotide with potent in vitro activity against a range of RNA viruses including Ebola virus, Marburg, MERS-CoV, SARS-CoV, respiratory syncytial virus, Nipah
virus, and Hendra virus [24–26]. The mechanism of action of remdesivir is premature termination of viral RNA transcription.

- Methylprednisolone 20 mg × 2/day, according to clinical/radiological judgment and the presence of any of these conditions:
  - Hypoxia at rest in ambient air (SpO2 < 93%, pO2 < 70 mmHg)
  - Respiratory rate > 30 acts/min in ambient air
  - P/F ratio ≤ 300 mmHg
  - CT scan with severe, extensive, bilateral interstitial involvement with fibrotic evolution
- Sodic Enoxaparin [27]:
  - Low-intensity care COVID-19 wards: 100 U/Kg/day; 70 U/Kg × 2/day for obese patient (BM1 > 30) or at particularly high thrombotic risk (e.g., neoplasms, previous DVT)
  - Intermediate/high-intensity care COVID-19 departments: 70 U/Kg × 2/day
- Antibiotic therapy: we suggest to use only in cases in which a superinfection cannot be excluded. For community-acquired forms of bacterial pneumonia (CAP), a third-generation cephalosporin, clarithromycin, or azithromycin or alternatively fluoroquinolones can be inserted, with attention to these last two due to the effect of elongation on QT.

In a low/intermediate care setting, such as the one in which we are working and to which this review is directed, we propose two possible therapeutic schemes, extrapolated from clinical experience and scientific evidence currently available but nevertheless continuously evolving, accelerated by the ongoing emergency. The schemes suggested are:

- Scheme A Hydroxychloroquine 200 mg × 2/day or 3/day (or chloroquine 500 mg × 2 day) [20] + lopinavir/ritonavir

### Table 1

| MEWS score | Heart rate | Systolic BP (mmHg) | Respiratory rate | Temperature (°C) | AVPU score |
|------------|------------|-------------------|-----------------|-----------------|------------|
| 3          | < 40       | 70–80             | < 9             | < 35.1           | A (alert)  |
| 2          | 40–50      | 81–100            | 9–14            | 35.1–36.5        | V (response to voice) |
| 1          | 51–100     | 101–200           | 15–20           | 36.6–37.5        | P (reacting to pain) |
| 0          | 101–110    | > 200             | 21–30           | > 37.5           | U (unresponsive) |
| > 2         | 111–130    |                   |                 |                 |            |
| > 3         | > 130      |                   |                 |                 |            |

BP blood pressure. AVPU score Alert-Voice-Pain-Unresponsive score

- Worried about patient’s condition, 1 point
- Urine production below 75 cc during previous 4 h, 1 point
- Saturation below 90% despite adequate oxygen therapy, 3 points

### Table 2

| Brescia-COVID Respiratory Severity Scale (BCRS) [9] |
| --- | --- | --- | --- | --- |
| Testing criteria |
| Patient has dyspnea or staccato speech (the patient is unable to count rapidly up to 20 after a deep breath) at rest or during minimal activity (sitting up in bed, standing, talking, swallowing, coughing) |
| Breathing rate > 22 |
| PaO2 < 65 mmHg or SpO2 < 90% |
| Significant worsening of chest X-ray |

| Criteria score | Action |
| --- | --- |
| 0 | Keep patients monitored with SpO2 and clinical evaluation |
| 1 | Add oxygen, keep patients monitored with SpO2 and clinical evaluation |
| 2 | Keep patients monitored with SpO2 and clinical evaluation, perform chest X-ray, gas analysis |
| > 2 but no NIV, HFNC, or CPAP | Keep patients monitored with SpO2 and clinical evaluation, perform chest X-ray every 2 days, gas analysis twice a day |
| > 2 and NIV, HFNC, or CPAP | Keep patients in ICU |

NIV noninvasive ventilation, HFNC high flow nasal cannula, CPAP continuous positive airway pressure, ICU intensive care unit
200/50 mg × 2/day (or darunavir/cobicistat 800/150 mg day or darunavir 800 mg day + ritonavir 100 mg day)

- Scheme B Hydroxychloroquine 200 mg × 2/day or 3/day (or chloroquine 500 mg × 2 day) [20] + azithromycin 500 mg day.

In Scheme A, in our unit, we prefer the use of darunavir + ritonavir or darunavir/cobicistat, although with less scientific evidence than lopinavir/ritonavir, because of its greater tolerability.

Scheme B seems to be supported by the recent publication of Gautret et al. that shows how hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients, effect reinforced by azithromycin [22]. However, the latest NIH COVID-19 guidelines panel and IDSA guideline panel recommend against this combination, except in the context of a clinical trial, for adverse effects, especially prolonged QTc interval [28, 21].

We consider the addition of heparin to these schemes if no contraindications are present.

Therapy should be continued for 7–20 days with timing to be established according to clinical evolution.

All these drugs have to be seriously evaluated for interactions with other therapy (in particular using lopinavir/ritonavir) and for the adverse events:

- Hydroxychloroquine and chloroquine can lengthen the QTc for which they need periodic ECG assessment and can lead to lesions of the retina and to glycidic intolerance.
- Azithromycin can also lengthen the QTc, which requires periodic ECG assessment.
- Lopinavir/ritonavir can cause diarrhea, nausea, vomiting, and increased amylase and lipase.
- Darunavir/cobicistat may give rise to creatinine, amylase, and lipase.
- Darunavir + ritonavir can increase amylase and lipase.

For the management of these drugs in relation to adverse effects on QTc interval, we refer to SIC guidelines (https://www.sicardiologia.it/public/SIC-Covid-e-QT.pdf), while for the possible interactions with other drugs, we consult http://www.covid19-druginteractions.org/.

Up to 20% of mild/moderate infections can develop into ARDS [2]. If rapid clinical deterioration during standard therapy occurs and oxygen therapy is needed, remdesivir can be used for compassionate use [29]. As soon as available, suspend Scheme A or B and continue with remdesivir 200 mg on day 1 then 100 mg/day for another 9 days in combination with chloroquine 500 mg, 1 × 2/day or hydroxychloroquine 200 mg, 1 × 2/day. If the patient develops a BCRSS score 3 or MEWS ≥ 3, evaluate dexamethasone and/or tociluzumab.

Tociluzumab should be administrated in apiretic patient > 72 h and/or at least 7 days after the onset of symptoms, if there is a worsening of gas exchange (BCRSS score ≥ 3) and if there are high levels of IL6 (or D-dimer and/or RCP and/or ferritin and/or fibrinogen increasing progressively). Patients aged < 18 years or with one or more of these conditions, transaminases greater than 5 times the norm, neutrophil value < 500 cell/mmc, PLT < 50,000 cells/mmc, sepsis, comorbidities related to an unfavorable outcome, diverticulitis or intestinal perforation, ongoing skin infection, and immunosuppressive antirejection therapy, should be excluded for tociluzumab therapy.

The therapeutic scheme recommended is for a maximum of 3 infusions at a dosage of 8 mg/kg body weight (maximum dosage per infusion 800 mg) with the second infusion done 8–12 h after the first. If clinical response is partial or incomplete, a third infusion 16–24 h after the first infusion is possible. After 24 h from the last administration, repeat the plasma dosage of IL-6 and/or D-dimer. Treatment must be accompanied by antiviral treatment (lopinavir/ritonavir or remdesivir + chloroquine/hydroxychloroquine) and/or steroid (dexamethasone) [30].

Type and Timing COVID-19 Positive Patient Assessment

In our low/medium intensity ward, we have drawn up a protocol of patient’s examinations to be requested both at the time of admission and during the course of the hospital stay, based from evidence and clinical judgment.

We present in details in Table 3.

Transfer and Discharge Criteria

COVID patients are in a delicate equilibrium, so they must be constantly monitored owing to the sudden high risk of clinical deterioration, especially during the second week of illness [2]. A patient who develops dyspnea, tachypnea (> 30 acts/min) with desaturation (SpO2 < 90%), and changes MEWS score in level 3–4 may require to be transferred to a subtensive critical area for the management of acute respiratory insufficiency and for noninvasive mechanical ventilation.

The appearance of respiratory distress, severe respiratory failure, diagnosis of ARDS, cardiovascular shock and multi-organ failure (MOF), severe agitation, severe sensory alteration, a state of epileptic illness, and serious arrhythmias potentially at risk of cardiovascular arrest led to a clinical reassessment with a MEWS score > 4, and the patient should be promptly transferred to an intensive care unit (ICU).
If the clinical course, on the other hand, is favorable and the patient meets both a clinical and laboratory improvement, two pathways open the following:

- Discharge at home when buffer is negative (at least two negative tests collected 24 h apart) and any symptoms of SARS-CoV-2 infection have disappeared.
- Discharge in care structures when buffer is positive but the patient is stably apiretic, the respiratory rate < 22 respiratory acts per minute and the oxygen saturation is > 95%.

**Conclusion**

Coronavirus disease 2019 (COVID-2019) is a rapidly spreading viral infection causing a severe acute respiratory syndrome that affects today about four and a half million people around the world. The purpose of this narrative review is to provide an urgent guidance for doctors taking care of patients in low/medium intensity care settings. We have tried to give management suggestions based on our experience and based on data collected from the international scientific evidence currently available but which is nonetheless continuously evolving, accelerated by the ongoing emergency. First of all, the patient’s stratification risk is to be established with severity score now available (MEWS or BCRSS); as soon as patients are hospitalized in non-intensivist wards, it is necessary to act with supportive therapeutic schemes, offer continuous clinical surveillance and be ready to recognize, and direct the patients who deteriorate into the sub-intensive and intensive areas. Secondly, we have to be able to identify the recovered patient and/or clinically healed, discharge, and give all the advice for keeping them and their relatives in safety.

In addition to our recommendations, we ask that the providers who care for the COVID-19 patients follow the specific policy in place by their institutions, hospitals, states, or federal governments to ensure that the patients’ management are in line with our guidance.

**Compliance with Ethical Standards**

**Conflict of Interest** The authors declare that they have no conflict of interest.
References

1. Coronavirus Resource Center at John Hopkins University & Medicine. Last accessed 15 May 2020. https://coronavirus.jhu.edu/map.html

2. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance. 2020. WHO/nCoV/ Clinical/2020.3

3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13): 1239–42. https://doi.org/10.1001/jama.2020.2648.

4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

5. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223): 507–13.

6. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23): 2526–33.

7. Royal College of Physicians of London. National early warning score (NEWS): standardising the assessment of acute-illness severity in the NHS—report of a working party. 2012. www.rcplondon.ac.uk/resources/national-early-warning-score-news. Last accessed 25 April 2020.

8. Subbe CP, Kruger M, Rutherford P, Gemmel L. Validation of a modified Early Warning Score in medical admissions. Q J Med. 2001;94(10):521–6.

9. Duca A, Piva S, Focà E, Latronico N, Rizzi M. Calculated decisions: Brescia-COVID Respiratory Severity Scale (BCRSS)/Algorithm. Emerg Med Pract. 2020;22(5 Suppl):CD1–2.

10. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60.

11. Chatterjee S. Important steps to control COVID-19/SARS-CoV-2 infection. SN Compr Clin Med. 2020;1(1–2). https://doi.org/10.1007/s42399-020-00271-7 PMID: 32292884; PMCID: PMC7140724.

12. Panati K, Narala VR. COVID-19 outbreak: an update on therapeutic options. SN Compr Clin Med. 2020;1(1–2). https://doi.org/10.1007/s42399-020-00264-6 PMID: 32292883; PMCID: PMC7110269.

13. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–6.

14. Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol. 2020;92(5):461–3.

15. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35(6):c79.

16. Savarino A, Di Trani L, Donatelli I, Cassone CR, A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006;6: 67–9.

17. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.

18. Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013;23(2):300–2.

19. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition):91406 Updated 发布时间:2020-03-16 12:00:32

20. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(3):185–8. Chinese. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.009.

21. IDSA guideline panel (http://www.idsociety.org/C OVID19guidelines Last updated April 21, 2020)

22. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020.

23. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–95. Erratum in: Blood. 2015 Aug 20;126(8):1048. Dosage error in article text. Blood. 2016 Sep 15;128(11):1533. https://doi.org/10.1182/blood-2014-05-552729.

24. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–5.

25. De Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020;117(12): 67716.

26. Sheahtn TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396).

27. Tang N, Bai H, Chen X, Gong J, Lin D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14817.

28. NIH COVID-19 guidelines panel. https://www.covid19treatmentguidelines.nih.gov/introduction/ last accessed 25 April 2020

29. Grein J, Ohmagari N, Shin D, et al. Compassionate use of chloroquine for COVID-19 pneumonia: an interim analysis of pooled case series. Travel Med Infect Dis. 2020;31:101678.

30. SIMIT Società Italiana di Malattie Infettive e Tropicali SEZIONE REGIONE LOMBARDIA Vademecum per la cura delle persone con malattia da COVID-19. Edizione 2.0, 13 marzo 2020

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.